Deciphera Pharmaceuticals IPO

9/27/2017

IPO

$127,500,000

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $60 million to fund clinical trials for DCC-2618, including the dose escalation and expansion stages of our current Phase 1 clinical trial and additional clinical trials, including a pivotal clinical trial in fourth-line GIST, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $6 million to fund clinical trials for DCC-3014, including the dose escalation stage of our Phase 1 clinical trial, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $6 million to fund clinical trials for rebastinib, as well as clinical research outsourcing and manufacturing of clinical trial material; approximately $10 million to fund the new and ongoing research activities for future drug candidates using our proprietary kinase switch control inhibitor platform; and the remainder

Publicly-held

Biopharmaceutical

200 Smith St.
Waltham, MA 02451
USA

Deciphera Pharmaceuticals (NASDAQ: DCPH) was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.